PHAT
Phathom Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$9.50
+4.97%Year over year
Reported trailing growth
- Revenue
- +110.2%
- EBITDA
- +86.3%
- EBIT
- +84.9%
- EPS
- +72.9%
- Free cash flow
- +86.6%
- Operating cash flow
- +86.6%
Forward estimates
Based on analyst estimates
- Revenue
- +65.5%
- EBITDA
- +342.8%
- EPS
- +108.3%
Three-year CAGR
- Revenue
- +1502.4%
- EBITDA
- +41.7%
- EBIT
- +42.3%
- Net income
- +33.8%
- EPS
- +42.7%
- Free cash flow
- +37.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026